Monthly information on share capital and company voting rights
September 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor
September 04, 2024 09:49 ET
|
BioAro
Biongevity appoints Harish Consul as Chief Venture Capital Advisor, accelerating global growth with innovative precision health and longevity strategies.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 04, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
September 03, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Appointment of Alan Huang, PhD, as Vice President of Sales
September 03, 2024 09:02 ET
|
Polarean
DURHAM, NC and LONDON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance...
Compass Therapeutics to Participate in Upcoming Investor Events
September 03, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024 07:45 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Present at Upcoming Investor Conferences
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET
|
23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
Fractyl Health to Participate in Upcoming September Investor Conferences
September 03, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences